{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T02:16:10Z","timestamp":1780366570188,"version":"3.54.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Real-world re-treatment intervals for botulinum toxins vary, but most subjects receive treatment less frequently than the manufacturer-recommended minimum intervals. In subjects receiving treatment with AbobotulinumtoxinA (ABO) less frequently, high levels of satisfaction and psychosocial improvements in well-being, self-confidence, and quality of life are observed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To evaluate subject satisfaction with a twice yearly re-treatment schedule.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS AND MATERIALS<\/jats:title>\n            <jats:p>This open-label, multicenter, interventional study evaluated subject satisfaction following injections of ABO 50 U in the glabellar lines at baseline and 6 months. The primary end point was subject satisfaction at 12 months. Secondary endpoints included subject satisfaction, FACE-Q scales, and glabellar line severity scale (GLSS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Ninety-five percent of the 120 subjects were \u201chighly satisfied\u201d or \u201csatisfied\u201d with their treatment outcomes at 12 months. FACE-Q total scores suggested that subjects were less bothered by glabellar lines and felt better about their facial appearance with each treatment versus baseline. Approximately half of subjects had \u22651-grade improvement from baseline in GLSS at 12 months. Median onset of effect was 2 days.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>The majority of subjects (95%) were satisfied with ABO treatment every 6 months; results were supported by high subject satisfaction, long duration, rapid onset, natural-looking results, and overall psychological wellness and safety.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000002846","type":"journal-article","created":{"date-parts":[[2020,11,8]],"date-time":"2020-11-08T15:02:55Z","timestamp":1604847775000},"page":"504-509","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["A Multicenter Study to Evaluate Subject Satisfaction With Two Treatments of AbobotulinumtoxinA a Year in the Glabellar Lines"],"prefix":"10.1097","volume":"47","author":[{"given":"Joel","family":"Schlessinger","sequence":"first","affiliation":[{"name":"Advanced Skin Research Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel L.","family":"Cohen","sequence":"additional","affiliation":[{"name":"University of California Irvine;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava","family":"Shamban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Jacob","sequence":"additional","affiliation":[{"name":"Chicago Cosmetic Surgery and Dermatology;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kian","family":"Karimi","sequence":"additional","affiliation":[{"name":"Rejuva Medical Aesthetics, Inc;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Maas","sequence":"additional","affiliation":[{"name":"University of California San Francisco;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Lane","sequence":"additional","affiliation":[{"name":"Medsense Ltd;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Coquis-Knezek","sequence":"additional","affiliation":[{"name":"Galderma Laboratories"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Meckfessel","sequence":"additional","affiliation":[{"name":"Galderma Laboratories"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,11,3]]},"reference":[{"key":"R1-20250731","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/DSS.0000000000002013","article-title":"Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines","volume":"46","author":"Monheit","year":"2020","journal-title":"Dermatol Surg"},{"key":"R4-20250731","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jaad.2003.11.084","article-title":"A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines","volume":"51","author":"Ascher","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"R5-20250731","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/archderm.142.3.320","article-title":"Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region","volume":"142","author":"Rzany","year":"2006","journal-title":"Arch Dermatol"},{"key":"R6-20250731","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1111\/j.1524-4725.2006.32332.x","article-title":"A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose","volume":"33","author":"Monheit","year":"2007","journal-title":"Dermatol Surg"},{"key":"R7-20250731","first-page":"439","article-title":"The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment","volume":"8","author":"Rubin","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"R8-20250731","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1111\/j.1524-4725.2009.01235.x","article-title":"Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety","volume":"35","author":"Brandt","year":"2009","journal-title":"Dermatol Surg"},{"key":"R9-20250731","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.asj.2009.09.010","article-title":"An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines","volume":"29","author":"Rubin","year":"2009","journal-title":"Aesthet Surg J"},{"key":"R10-20250731","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/archfaci.2009.5","article-title":"Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines","volume":"11","author":"Moy","year":"2009","journal-title":"Arch Facial Plast Surg"},{"issue":"suppl 1","key":"R11-20250731","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03475.x","article-title":"Treatment of glabellar lines with botulinum toxin type A (Speywood Unit): a clinical overview","volume":"24","author":"Rzany","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R12-20250731","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1111\/j.1524-4725.2006.32327.x","article-title":"Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients","volume":"33","author":"Rzany","year":"2007","journal-title":"Dermatol Surg"},{"key":"R13-20250731","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1007\/s00266-018-1200-4","article-title":"Assessment of subject and physician satisfaction after long-term treatment of glabellar lines with AbobotulinumtoxinA (Dysport\u00ae\/Azzalure\u00ae): primary results of the APPEAL noninterventional study","volume":"42","author":"Gubanova","year":"2018","journal-title":"Aesth Plast Surg"},{"key":"R14-20250731","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/PSN.0000000000000292","article-title":"AbobotulinumtoxinA for facial rejuvenation: what affects the duration of efficacy?","volume":"40","author":"Warren","year":"2020","journal-title":"Plast Surg Nurs"},{"key":"R15-20250731","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/PRS.0000000000006327","article-title":"DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)","volume":"145","author":"Caruthers","year":"2020","journal-title":"Plast Reconstr Surg"},{"issue":"suppl 1","key":"R16-20250731","first-page":"AB250","article-title":"Safety and efficacy of escalating doses of incobotulinumtoxina for extended treatment of glabellar frown lines: a randomized double-blind study","volume":"79","author":"Maas","year":"2018","journal-title":"JAAD"},{"key":"R17-20250731","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/DSS.0000000000001940","article-title":"Assessment of psychological well-being after abobotulinumtoxinA treatment: a comparison of 2 reconstitution volumes","volume":"46","author":"Cohen","year":"2020","journal-title":"Dermatol Surg"},{"issue":"suppl 4","key":"R18-20250731","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1111\/j.1524-4725.2010.01795.x","article-title":"A double-blind, randomized, placebo-controlled health-outcomes survey of the effect of botulinum toxin type A injections on quality of life and self-esteem","volume":"36","author":"Dayan","year":"2010","journal-title":"Dermatol Surg"},{"key":"R19-20250731","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/asj\/sjv244","article-title":"Patient perceived benefit in facial aesthetic procedures: FACE-Q as a tool to study botulinum toxin injection outcomes","volume":"36","author":"Chang","year":"2016","journal-title":"Aesthet Surg J"},{"key":"R20-20250731","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/asj\/sjx179","article-title":"Impact of comprehensive, minimally invasive, multimodal aesthetic treatment on satisfaction with facial appearance: the HARMONY study","volume":"38","author":"Weinkle","year":"2018","journal-title":"Aesthet Surg J"},{"key":"R21-20250731","first-page":"41","article-title":"Impact of botulinum toxin a on the quality of life of subjects following treatment of facial lines","volume":"6","author":"Jandhyala","year":"2013","journal-title":"J Clin Aesthet Dermatol"},{"key":"R22-20250731","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1097\/DSS.0000000000001926","article-title":"Clinical assessment of 2 licensed AbobotulinumtoxinA Injection volumes for the treatment of glabellar lines","volume":"45","author":"Kaufman","year":"2019","journal-title":"Dermatol Surg"},{"key":"R23-20250731","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/toxins10120535","article-title":"AbobotulinumtoxinA (Dysport\u00ae), OnabotulinumtoxinA (Botox\u00ae), and IncobotulinumtoxinA (Xeomin\u00ae) neurotoxin content and potential implications for duration of response in patients","volume":"10","author":"Field","year":"2018","journal-title":"Toxins"},{"key":"R24-20250731","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum neurotoxins: biology, pharmacology, and toxicology","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharmacol Rev"},{"key":"R25-20250731","first-page":"1382","article-title":"Patient satisfaction after the treatment of glabellar lines with botulinum toxin type A (Speywood Unit): a multi-centre European observational study","volume":"29","author":"Molina","year":"2015","journal-title":"JEADV"},{"key":"R26-20250731","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/j.1524-4725.2011.02075.x","article-title":"Time to onset of response of abobotulinumtoxina in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type A","volume":"37","author":"Schlessinger","year":"2011","journal-title":"Dermatol Surg"},{"key":"R27-20250731","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archfaci.2011.1142","article-title":"Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA","volume":"14","author":"Yu","year":"2012","journal-title":"Arch Facial Plast Surg"},{"key":"R28-20250731","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/01.smj.0000220888.88722.ab","article-title":"Effectiveness of repeated treatment with botulinum toxin type A across different conditions","volume":"99","author":"Gordon","year":"2006","journal-title":"South Med J"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000002846","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:13:06Z","timestamp":1753999986000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000002846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,3]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000002846","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,3]]}}}